Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Institution Directory

Clinical trials at Yale

Sites in New Haven, CT

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 26, 2026, 6:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
1242
Shown on this page
12
Current sort
Recently updated
Campus scope
Yale, New Haven, CT
Additional filters apply within this campus.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this campus

These controls apply only within Yale, New Haven, CT. Default order is Recently updated. Add condition, therapy, sponsor, or recruitment status to narrow this page further.

Reset campus filters
Clear filters
Showing 805–816 of 1,242 matching trials with a site at Yale, New Haven, CT.
Live ClinicalTrials.gov results.
Local aggregate panels are unavailable or hidden for filtered views. The result list above identifies its data source.

Live official records

Active, not recruiting Phase 3 Interventional

Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

NCT03488693
Site status not listed — check the official record
View directory record Official record
Conditions
Breast Cancer
Interventions
Radiation, No Radiation
Radiation · Other
Lead sponsor
Canadian Cancer Trials Group
Network
Eligibility
35 Years and older · Female only
Enrollment
2,138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2027
U.S. locations
451
States / cities
Fairbanks, Alaska • Gilbert, Arizona • Phoenix, Arizona + 349 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment Pumitamig (BNT327) and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer

NCT07079631
Status at this site: Recruiting
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
BNT314, Pumitamig, SoC chemotherapy treatment 1, SoC chemotherapy treatment 2, Bevacizumab
Biological · Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
482 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
4
States / cities
New Haven, Connecticut • Grand Rapids, Michigan • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Not yet recruiting Not applicable Interventional

Effect of HBOT on Femoral Head Avascular Necrosis (AVN)

NCT06931301
Site status not listed — check the official record
View directory record Official record
Conditions
Osteonecrosis, Avascular Necrosis
Interventions
Hyperbaric Oxygen Therapy
Device
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Active, not recruiting Not applicable Interventional

Recovery Finance: Financial Health and Mental Health After Incarceration

NCT06914856
Site status not listed — check the official record
View directory record Official record
Conditions
Financial Hardship, Mental Health Issue, Substance Use
Interventions
Financial Capability Support with Peer Support Services
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
238 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Recruiting Not applicable Interventional

Simulation Trial of Telemedical Support for Paramedics

NCT06441760
Status at this site: Active, not recruiting
View directory record Official record
Conditions
Emergencies, Cardiopulmonary Arrest, Acute Respiratory Failure, Status Epilepticus
Interventions
Video teleconsultation, Audio support
Other
Lead sponsor
Boston Medical Center
Other
Eligibility
21 Years and older
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
9
States / cities
Los Angeles, California • Aurora, Colorado • New Haven, Connecticut + 6 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Active, not recruiting Phase 2 Interventional

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy

NCT06449222
Site status not listed — check the official record
View directory record Official record
Conditions
Locally Advanced Breast Cancer, Triple Negative Breast Cancer, Metastatic Triple Negative Breast Cancers
Interventions
BNT327 Dose Level 1 (DL1), BNT327 Dose Level 1 (DL2), Nab-placlitaxel, Carboplatin, Gemcitabine, Paclitaxel, Eribulin, BNT327 Optimized Dose, BNT327 Equivalent Q3W Dose
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
13
States / cities
Beverly Hills, California • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Recruiting Phase 3 Interventional

Pre-Operative Window of ET to Inform RT Decisions (POWER II)

NCT06507618
Status at this site: Recruiting
View directory record Official record
Conditions
Breast Cancer Female
Interventions
Tamoxifen, Letrozole, Anastrozole, or Exemestane
Drug
Lead sponsor
University of Virginia
Other
Eligibility
65 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2034
U.S. locations
6
States / cities
New Haven, Connecticut • Charlottesville, Virginia • Culpeper, Virginia + 3 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study to Investigate ALE.P02 as Monotherapy in Adult Patients With Selected CLDN1+ Solid Tumors

NCT06747585
Status at this site: Recruiting
View directory record Official record
Conditions
Squamous Non-small-cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Cervical Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma
Interventions
ALE.P02
Drug
Lead sponsor
Alentis Therapeutics AG
Industry
Eligibility
18 Years and older
Enrollment
170 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
8
States / cities
Scottsdale, Arizona • Fullerton, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Active, not recruiting Phase 3 Interventional

To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis

NCT05908084
Site status not listed — check the official record
View directory record Official record
Conditions
End Stage Renal Disease (ESRD)
Interventions
Acellular Tissue Engineered Vessel (ATEV), AVF
Biological · Other
Lead sponsor
Humacyte, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
32
States / cities
Scottsdale, Arizona • El Centro, California • La Jolla, California + 25 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Recruiting Phase 2 Interventional

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

NCT05650229
Status at this site: Not yet recruiting
View directory record Official record
Conditions
Primary Mitochondrial Disease
Interventions
KL1333, Placebo
Drug
Lead sponsor
Pharming Technologies B.V.
Industry
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
20
States / cities
Orange, California • San Diego, California • San Francisco, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Recruiting Phase 3 Interventional

Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

NCT04045665
Status at this site: Recruiting
View directory record Official record
Conditions
Atrial Fibrillation, Stroke, Bleeding
Interventions
Antiplatelet-only strategy, Oral Anticoagulant plus background antiplatelet therapy
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
3,200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
51
States / cities
Little Rock, Arkansas • Los Angeles, California • Stanford, California + 40 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 6:07 AM EDT
Active, not recruiting Phase 1 Interventional

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma

NCT02520791
Site status not listed — check the official record
View directory record Official record
Conditions
Advanced Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3a Follicular Lymphoma, Recurrent Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Follicular Helper T-Cell Lymphoma, Angioimmunoblastic-Type, Refractory Grade 1 Follicular Lymphoma, Refractory Grade 2 Follicular Lymphoma, Refractory Grade 3a Follicular Lymphoma, Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma, Stage IB Mycosis Fungoides AJCC v7, Stage II Mycosis Fungoides AJCC v7, Stage III Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage III Mycosis Fungoides AJCC v7, Stage IV Cutaneous T-Cell Non-Hodgkin Lymphoma, Stage IV Mycosis Fungoides AJCC v7
Interventions
Anti-ICOS Monoclonal Antibody MEDI-570, Laboratory Biomarker Analysis, Pharmacological Study
Biological · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
21
States / cities
Duarte, California • Sacramento, California • New Haven, Connecticut + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 26, 2026, 6:07 AM EDT

About this Yale institution page

What this page lists
ClinicalTrials.gov records that list Yale in New Haven, CT as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status
A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from
Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do
No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Related: all institution pages, trials led by Yale University at any site, browse by condition, or browse by U.S. city.